Zhifei Biological's pneumococcal vaccine application accepted

Chongqing Zhifei Biological Products (SZSE:300122) announced that its subsidiary, Zhifei Green Bamboo Biological Pharmaceutical, has received notification from the National Medical Products Administration that its application for production registration of its 15-valent pneumococcal conjugate vaccine has been accepted. According to the company, this vaccine targets 15 serotypes of pneumococcal bacteria prevalent in Asia and domestically. The company notes that pneumococcal bacteria are major cause of lower respiratory infections, leading to an estimated 97.9 million cases and 500,000 deaths globally in 2021. Zhifei Biological already markets a 23-valent pneumococcal polysaccharide vaccine and has a 26-valent vaccine in clinical trials.